EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis

Lili Korpás, Ádám Wiedemann, Fruzsina Szél, Szabolcs Svorenj, Júlia Weisinger, Zsolt Nagy, Zsuzsanna Szemlaky, Zoltán Csukly, Péter Reményi iD, Péter Rajnics, Elvira Altai, Márk Plander und 12 weitere

Cancers · 06.11.2026 · 18 (21) · 3565

DOI: 10.3390/cancers18213565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 06.11.2026. Verfasst von Lili Korpás und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Haematology, Semmelweis University, 1085 Budapest, Hungary. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Dexamethasone has long served as the cornerstone of therapy for multiple myeloma; however, its optimal dosing remains ill-defined, particularly when balanced against its profound toxicity profile. Recent therapeutic advances have consequently intensified interest in steroid dose-reduction strategies. This retrospective, multicenter study aimed to evaluate the impact of varied dexamethasone dosing regimens on clinical outcomes within a real-world setting.

Methods

We conducted a retrospective multicenter study across 11 Hungarian centers, enrolling 272 patients with multiple myeloma who received lenalidomide–dexamethasone therapy. Treating physicians determined dosing strategies at their discretion for each patient. We retrospectively stratified patients into three cohorts based on their prescribed weekly dexamethasone dose: 40 mg, 20 mg, and less than 20 mg.

Results

We observed a distinct interaction between patient age and weekly dexamethasone dose. Nonetheless, we detected no statistically significant difference in progression-free survival (PFS) among the three dosing cohorts (p = 0.632). Similarly, dexamethasone dose intensity demonstrated no significant association with overall treatment response (p = 0.560). Subgroup analysis restricted to patients with high-risk cytogenetics also showed no significant disparities in PFS (p = 0.312). Furthermore, early treatment response rates at 2 and 6 months were also independent of the dexamethasone dose. Notably, grade 3–5 adverse events were numerically more frequent in the 40 mg group. The lack of significant differences in these outcome measures is particularly important, given the baseline age imbalances among the cohorts.

Conclusions

Lower initial dexamethasone dose was not associated with statistically significant differences in progression-free survival or treatment response in this retrospective cohort. Although Grade 3–5 adverse events were numerically more frequent in the 40 mg group, these observations warrant further investigation in prospective studies.

Schlagwörter

Stichwörter der Autor:innen

dexamethasone dose reductionlenalidomide-dexamethasonemultiple myeloma

Autor:innen und Institutionen

  • Department of Internal Medicine and Haematology, Semmelweis University, 1085 Budapest, Hungary.
  • Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, 1097 Budapest, Hungary.
  • Somogy County Kaposi Mór Teaching Hospital, 7400 Kaposvár, Hungary.
  • Hematology, Veszprém-Csolnoky Ferenc County Hospital, 8200 Veszprém, Hungary.
  • Markusovszky University Teaching Hospital, 9700 Szombathely, Hungary.
  • Borsod-Abaúj-Zemplén Central County University Teaching Hospital, 3526 Miskolc, Hungary.

ORCID-Profile: Péter Reményi, Hussain Alizadeh, Tamás Masszi, Gergely Varga

Zitieren

APA

Korpás, L., Wiedemann, Á., Szél, F., Svorenj, S., Weisinger, J., Nagy, Z., Szemlaky, Z., Csukly, Z., Reményi, P., Rajnics, P., Altai, E., Plander, M., Kórád, K., Szaleczky, E., Masszi, A., Kosztolányi, S., Alizadeh, H., Modok, S., Borbényi, Z., …, & Varga, G. (2026). Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis. Cancers, 18(21), 3565. https://doi.org/10.3390/cancers18213565

Vancouver

Korpás L, Wiedemann Á, Szél F, Svorenj S, Weisinger J, Nagy Z, et al. Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis. Cancers. 2026;18(21):3565. doi:10.3390/cancers18213565

BibTeX
@article{Korps2026,
  author = {Korpás, Lili and Wiedemann, Ádám and Szél, Fruzsina and Svorenj, Szabolcs and Weisinger, Júlia and Nagy, Zsolt and Szemlaky, Zsuzsanna and Csukly, Zoltán and Reményi, Péter and Rajnics, Péter and Altai, Elvira and Plander, Márk and Kórád, Krisztina and Szaleczky, Erika and Masszi, András and Kosztolányi, Szabolcs and Alizadeh, Hussain and Modok, Szabolcs and Borbényi, Zita and Lovas, Szilvia and Váróczy, László and Masszi, Tamás and Mikala, Gábor and Varga, Gergely},
  title = {Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3565},
  doi = {10.3390/cancers18213565}
}
Kostenlos starten →